Skip to main content

Apollomics Inc.

corporate_fare Company Profile

Apollomics Inc.

APLM·NASDAQ·Life Sciences·CIK 0001944885

Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer treatments. The company's approach involves harnessing the immune system and targeting specific molecular pathways to inhibit cancer growth. Its product portfolio includes Vebreltinib (APL-101), an oral, highly selective c-Met inhibitor currently in Phase 2 clinical trials for non-small cell lung cancer and other solid tumors with MET dysregulation. APL-102, an oral small molecule multiple tyrosine kinase inhibitor, is in a Phase 1 clinical trial to inhibit various kinases activated in cancer cells. Additionally, APL-122 is a tumor inhibitor candidate targeting ErbB1/2/4 signaling pathways, which is in Phase 1 dose escalation clinical trials for treating brain cancers. The company also has immuno-oncology product candidates, including APL-501, APL-502, and APL-801. Apollomics, Inc. was founded in 2015 and is based in Foster City, California.

Apollomics Inc. (NASDAQ:APLM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for APLM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-17, rated 9/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for APLM spans 4, SCHEDULE 13D/A, 6-K, 20-F.

Recent high-impact activity:

  • CFO Invests $400K in Private Placement, Boosting Insider Confidence
  • CEO Chen Acquires 536,667 Shares in $5.55M PIPE, Boosting Stake to 49.76%
  • $10M Private Placement Priced at $15/Share, Insiders Participate
  • Apollomics Regains Nasdaq Compliance, Delisting Threat Lifted
  • Apollomics Terminates Key Partnership Due to Material Breach, Initiates Dispute Resolution

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$8.5M
Net Income
-$10.94M
Diluted EPS
-$7.57
Op. Cash Flow
-$10.37M
Cash & Equivalents
$3.28M
Debt / Equity
0.00×
Net Margin
-128.7%
Source: 20-F · filed 2026-04-24 · accession 0001193125-26-177357

Dilution Risk

Low risk

Filing-implied dilution signals for APLM, detected from its recent SEC filings · based on capital-structure filings through 2026-09-08.

1 recent capital raise

279,775 PIPE Shares Registered for Resale · Selling Securityholders Identified

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

APLM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$24.02 +0.84% today
52-week range · as of 2026-08-17 $3.66 – $42.12
Market cap
$70.02M
Volume
4K (0.2× avg)
3-mo avg 24.2K
Live data · 2026-09-15 15:46 UTC · Market open

show_chartPrice Chart

Loading chart...

feed APLM - Latest Insights

APLM
Aug 17, 2026, 7:23 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $23.55
Real-time Price: $24.02 info
Change: +$0.470 (+2%) info
Market Cap: $70.017M info
APLM
Aug 17, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.55
Real-time Price: $24.02 info
Change: +$0.470 (+2%) info
Market Cap: $70.017M info
APLM
Aug 11, 2026, 4:35 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.16
Real-time Price: $24.02 info
Change: +$5.86 (+32%) info
Market Cap: $70.017M info
APLM
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.95
Real-time Price: $24.02 info
Change: +$5.07 (+27%) info
Market Cap: $70.017M info
APLM
Jun 24, 2026, 6:28 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $20.50
Real-time Price: $24.02 info
Change: +$3.52 (+17%) info
Market Cap: $70.017M info
APLM
Jun 24, 2026, 5:11 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $20.50
Real-time Price: $24.02 info
Change: +$3.52 (+17%) info
Market Cap: $70.017M info
APLM
Apr 27, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $13.28
Real-time Price: $24.02 info
Change: +$10.74 (+81%) info
Market Cap: $70.017M info
APLM
Apr 24, 2026, 4:24 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $13.28
Real-time Price: $24.02 info
Change: +$10.74 (+81%) info
Market Cap: $70.017M info
APLM
Apr 08, 2026, 7:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $15.40
Real-time Price: $24.02 info
Change: +$8.62 (+56%) info
Market Cap: $70.017M info
APLM
Apr 01, 2026, 4:52 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $14.72
Real-time Price: $24.02 info
Change: +$9.30 (+63%) info
Market Cap: $70.017M info
APLM
Mar 09, 2026, 5:16 PM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $20.01
Real-time Price: $24.02 info
Change: +$4.01 (+20%) info
Market Cap: $70.017M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets